Albert Jang, MD, discusses the promise of using ctDNA to determine whether patients with advanced genitourinary cancers are responding to immune checkpoint inhibitors.
Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses the study, “Prospective Evaluation Of Circulating Tumor Dna (ctDNA) in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Cancers,” which he shared at the 2022 AUA Annual Meeting.
Expert explains everything urologists need to know on genomic testing
November 15th 2022All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications, according to Emmanuel S. Antonarakis, MD.
Novel biomarker emerges for salvage RT approach in biochemically recurrent prostate cancer
November 11th 2022A higher score on PORTOS, an expression signature of 24 DNA damage repair and immune pathway genes, predicted improved response to dose-intensified salvage radiotherapy after radical prostatectomy in patients with biochemically recurrent prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512